Skip to main content

Pharma News

 

Clinical courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Spending on programmes to control India’s three main communicable diseases malaria, tuberculosis and leprosy increased seven percent over five years while cases reported, taken together, increased 32 percent, according to an IndiaSpend analysis of government data.

    (adsbygoogle = window.adsbygoogle || []).push({});
  • Malaria, a life-threatening disease caused by parasites that are transmitted to people through mosquitoe bites, started out as a parasite in birds, and then it evolved to colonise bats, and from there it has evolved to affect other mammals, reveals a new study.

  • The Reston virus, a member of the Ebola virus family which is known to circulate in domestic pigs in Asia, may acquire the few mutations necessary to cause disease in humans and to develop into a novel health threat, researchers have warned.

  • With the government announcing eradication of tuberculosis by 2030, a doctor has says a new 'Endobroncial Ultrasound' medical process that was introduced in India recently can contribute in faster diagnosis of the disease leading to correct treatment on time.

  • Glenmark Pharmaceuticals has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for its Lacosamide Oral Solution, 10 mg/mL, the generic version of Vimpat® Oral Solution, 10 mg/mL of UCB, Inc. Glenmark will market this product upon receiving final approval of its Lacosamide Oral Solution, 10 mg/mL ANDA. The patent listed in the Orange Book for Vimpat® Oral Solution, 10 mg/mL is scheduled to expire on March 17, 2022.

  • Albumedix announced that its albumin-based VELTIS® half-life extension technology is being used by CSL Behring in IDELVION®, a  therapy recently authorized for the treatment of haemophilia B in the U.S. The application of Albumedix’s VELTIS technology in the drug delivers an extended half-life which will improve the lives of patients living with the condition by reducing the frequency of injections up to once every 14 days. The U.S. Centers for Disease Control and Prevention, report that the condition affects approximately one in 25,000 male births.

  • Anacor Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review Anacor's New Drug Application (NDA) seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults.

  • Aratana Therapeutics, Inc., a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced the Food and Drug Administration's Center for Veterinary Medicine (CVM) approved GALLIPRANT® (grapiprant tablets) for the control of pain and inflammation associated with osteoarthritis in dogs.

Subscribe to Pharma News